Interaction between APOE4 and herpes simplex virus type 1 in Alzheimer's disease.
APOE4
Alzheimer's disease
dementia
genetic susceptibility
herpes virus
prevention
Journal
Alzheimer's & dementia : the journal of the Alzheimer's Association
ISSN: 1552-5279
Titre abrégé: Alzheimers Dement
Pays: United States
ID NLM: 101231978
Informations de publication
Date de publication:
01 2020
01 2020
Historique:
received:
04
07
2019
revised:
28
10
2019
accepted:
18
11
2019
entrez:
9
1
2020
pubmed:
9
1
2020
medline:
31
10
2020
Statut:
ppublish
Résumé
Numerous results suggest the implication of infectious agents in the onset of Alzheimer's disease (AD). In the Bordeaux-3C prospective cohort, we assessed the impact of herpes simplex virus type 1 (HSV-1) infection on the incidence of AD according to apolipoprotein E (APOE) status, a genetic susceptibility factor. Cox models were performed to estimate the 10-year risk of AD associated with anti-HSV antibodies in 1037 participants according to APOE4 status. Among APOE4 carriers, subjects for whom the frequency of HSV-1 reactivation is supposed to be high, that is, immunoglobulin M (IgM) positive or elevated levels of IgG, had an increased risk of AD with adjusted hazard ratios (HRs) of 3.68 (1.08-12.55) and 3.28 (1.19-9.03), respectively. No significant association was found in APOE4-negative subjects. These results, in accordance with a solid pathophysiological rationale, suggest a role for HSV-1 in AD development among subjects with a genetic susceptibility factor, the APOE4 allele.
Substances chimiques
Apolipoprotein E4
0
Immunoglobulin M
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
200-208Informations de copyright
© 2020 the Alzheimer's Association.
Références
Querfurth HW, LaFerla FM. Alzheimer's disease. N Engl J Med. 2010;362:329-344.
Moir RD, Lathe R, Tanzi RE. The antimicrobial protection hypothesis of Alzheimer's disease. Alzheimers Dement. 2018;14:1602-1614.
Soscia SJ, Kirby JE, Washicosky KJ, et al. The Alzheimer's disease-associated amyloid β-protein is an antimicrobial peptide. PLoS One. 2010;5:e9505.
Bourgade K, Dupuis G, Frost EH, Fülöp T. Anti-viral properties of amyloid-β peptides. J Alzheimers Dis. 2016;54:859-878.
Karch CM, Goate AM. Alzheimer's disease risk genes and mechanisms of disease pathogenesis. Biol Psychiatry. 2015;77:43-51.
Carter CJ. Interactions between the products of the herpes simplex genome and Alzheimer's disease susceptibility genes: relevance to pathological-signalling cascades. Neurochem Int. 2008;52:920-934.
Carter C. Alzheimer's disease: APP, gamma secretase, APOE, CLU, CR1, PICALM, ABCA7, BIN1, CD2AP, CD33, EPHA1, and MS4A2, and their relationships with herpes simplex, C. pneumoniae, other suspect pathogens, and the immune system. Int J Alzheimers Dis. 2011;2011:501862.
Itzhaki RF, Lathe R, Balin BJ, et al. Microbes and Alzheimer's disease. J Alzheimers Dis. 2016;51:979-984.
Bellon M, Nicot C. Telomere dynamics in immune senescence and exhaustion triggered by chronic viral infection. Viruses. 2017;9:289.
Fulop T, Larbi A, Dupuis G, et al. Immunosenescence and inflamm-aging as two sides of the same coin: friends or foes? Front Immunol. 2018;8:1960.
Itzhaki RF. Corroboration of a major role for herpes simplex virus type 1 in Alzheimer's disease. Front Aging Neurosci. 2018;10:324.
Steel AJ, Eslick GD. Herpes viruses increase the risk of Alzheimer's disease: a meta-analysis. J Alzheimers Dis. 2015;47:351-364.
Wozniak M, Mee A, Itzhaki R. Herpes simplex virus type 1 DNA is located within Alzheimer's disease amyloid plaques. J Pathol. 2009;217:131-138.
Harris SA, Harris EA. Molecular mechanisms for herpes simplex virus type 1 pathogenesis in Alzheimer's disease. Front Aging Neurosci. 2018;10:48.
Letenneur L, Pérès K, Fleury H, et al. Seropositivity to herpes simplex virus antibodies and risk of Alzheimer's disease: a population-based cohort study. PLoS One. 2008;3:e3637.
Lövheim H, Gilthorpe J, Adolfsson R, Nilsson L-G, Elgh F. Reactivated herpes simplex infection increases the risk of Alzheimer's disease. Alzheimers Dement. 2015;11:593-599.
Looker K, Garnett G. A systematic review of the epidemiology and interaction of herpes simplex virus types 1 and 2. Sex Transm Infect. 2005;81:103-107.
Abel L, Fellay J, Haas DW, et al. Genetics of human susceptibility to active and latent tuberculosis: present knowledge and future perspectives. Lancet Infect Dis. 2018;18:e64-e75.
Verghese PB, Castellano JM, Holtzman DM. Apolipoprotein E in Alzheimer's disease and other neurological disorders. Lancet Neurol. 2011;10:241-252.
Itzhaki R, Wozniak M. Herpes simplex virus type 1, apolipoprotein E, and cholesterol: a dangerous liaison in Alzheimer's disease and other disorders. Prog Lipid Res. 2006;45:73-90.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV. Washington, DC: American Psychiatric Association; 1994.
The 3C Study Group. Vascular factors and risk of dementia: design of the Three-City Study and baseline characteristics of the study population. Neuroepidemiology. 2003;22:316-325.
Bünzli D, Wietlisbach V, Barazzoni F, Sahli R, Meylan PR. Seroepidemiology of Herpes Simplex virus type 1 and 2 in Western and Southern Switzerland in adults aged 2574 in 1992-93: A population-based study. BMC Infect Dis. 2004;4:10.
Malkin J-E. Seroprevalence of HSV-1 and HSV-2 infection in the general French population. Sexually Transmitted Infections. 2002;78:201-203.
Håkansson K, Rovio S, Helkala E-L, et al. Association between mid-life marital status and cognitive function in later life: population based cohort study. BMJ. 2009;339:b2462.
Warren-Gash C, Forbes HJ, Williamson E, et al. Human herpesvirus infections and dementia or mild cognitive impairment: a systematic review and meta-analysis. Sci Rep. 2019;9:4743.
Costa AS, Agostini S, Guerini FR, et al. Modulation of immune responses to herpes simplex virus type 1 by IFNL3 and IRF7 polymorphisms: a study in Alzheimer's disease. J Alzheimers Dis. 2017;60:1055-1063.
Mancuso R, Baglio F, Agostini S, et al. Relationship between herpes simplex virus-1-specific antibody titers and cortical brain damage in Alzheimer's disease and amnestic mild cognitive impairment. Front Aging Neurosci. 2014;6:285.
Lövheim H, Norman T, Weidung B, et al. Herpes simplex virus, APOE ɛ4, and cognitive decline in old age: results from the Betula Cohort Study. J Alzheimers Dis. 2019;67:211-220.
Lövheim H, Gilthorpe J, Johansson A, Eriksson S, Hallmans G, Elgh F. Herpes simplex infection and the risk of Alzheimer's disease: a nested case-control study. Alzheimers Dement. 2015;11:587-592.
Lord A, Sutton RNP, Baker AA, Hussein SAM. Serological studies in the elderly. Age Ageing. 1978;7:116-122.
Whalley LJ, Urbaniak SJ, Darg C, Peutherer JF, Christie JE. Histocompatibility antigens and antibodies to viral and other antigens in Alzheimer pre-senile dementia. Acta Psychiatr Scand. 1980;61:1-7.
Renvoize EB, Awad LO, Hambling MH. A sero-epidemiological study of conventional infectious agents in Alzheimer's disease. Age Ageing. 1987;16:311-314.
Liu T, Khanna KM, Chen X, Fink DJ, Hendricks RL. CD8(+) T cells can block herpes simplex virus type 1 (HSV-1) reactivation from latency in sensory neurons. J Exp Med. 2000;191(9):1459-1466.
Lövheim H, Olsson J, Weidung B, et al. Interaction between cytomegalovirus and herpes simplex virus type 1 associated with the risk of Alzheimer's disease development. J Alzheimers Dis. 2018;61:939-945.
Burgos JS, Ramirez C, Sastre I, Bullido MJ, Valdivieso F. APOE4 is more efficient than E3 in brain access by herpes simplex virus type. Genetics of Nervous System Disease. 2003;14:3.
Burgos JS, Ramirez C, Sastre I, Valdivieso F. Effect of apolipoprotein E on the cerebral load of latent herpes simplex virus type 1 DNA. J Virol. 2006;80:5383-5387.
Guzman-Sanchez F, Valdivieso F, Burgos JS. Aging-related neurostructural, neuropathological, and behavioral changes associated with herpes simplex virus type 1 brain infection in mice. J Alzheimers Dis. 2012;30:779-790.
Lin W-R, Shang D, Wilcock GK, Itzhaki RF. Alzheimer's disease, herpes simplex virus type 1, cold sores and apolipoprotein E4. Biochem Soc Trans. 1995;23(4):594S.
Koelle DM, Magaret A, Warren T, Schellenberg GD, Wald A. APOE genotype is associated with oral herpetic lesions but not genital or oral herpes simplex virus shedding. Sex Transm Infect. 2010;86:202-206.
Itzhaki RF, Lin W-R, Shang D, Wilcock GK, Faragher B, Jamieson GA. Herpes simplex virus type 1 in brain and risk of Alzheimer's disease. Lancet North Am Ed. 1997;349:241-244.
Itzhaki RF, Wozniak MA. Herpes simplex virus type 1 in Alzheimer's disease: the enemy within. J Alzheimers Dis. 2008;13:393-405.
Corder EH, Robertson K, Lannfelt L, et al. HIV-infected subjects with the E4 allele for APOE have excess dementia and peripheral neuropathy. Nat Med. 1998;4:1182-1184.
Urosevic N, Martins RN. Infection and Alzheimer's disease: the APOE ε4 connection and lipid metabolism. J Alzheimers Dis. 2008;13:421-435.
Miyata M, Smith JD. Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxicity by oxidative insults and beta-amyloid peptides. Nat Genet. 1996;14:7.
Carter CJ. Alzheimer's disease plaques and tangles: cemeteries of a pyrrhic victory of the immune defence network against herpes simplex infection at the expense of complement and inflammation-mediated neuronal destruction. Neurochem Int. 2011;58:301-320.
Khachaturian ZS, Mesulam M-M, Khachaturian AS, Mohs RC. The special topics section of Alzheimer's & dementia. Alzheimers Dement. 2015;11:1261-1264.
Wozniak MA, Frost AL, Preston CM, Itzhaki RF. Antivirals reduce the formation of key Alzheimer's disease molecules in cell cultures acutely infected with herpes simplex virus type 1. PLoS One. 2011;6:e25152.
Wozniak MA, Frost AL, Itzhaki RF. The helicase-primase inhibitor BAY 57-1293 reduces the Alzheimer's disease-related molecules induced by herpes simplex virus type 1. Antiviral Res. 2013;99:401-404.
Lin W-R, Jennings R, Smith TL, Wozniak MA, Itzhaki RF. Vaccination prevents latent HSV1 infection of mouse brain. Neurobiol Aging. 2001;22:699-703.